tacrolimus + FOLFOX4

Tacrolimus + FOLFOX4 is a combination therapy involving the immunosuppressant tacrolimus and the chemotherapy regimen FOLFOX4. Tacrolimus is a calcineurin inhibitor used primarily to prevent organ transplant rejection by suppressing T-cell activation. FOLFOX4 is a specific protocol of the FOLFOX chemotherapy regimen, which includes oxaliplatin (a platinum-based DNA crosslinker), folinic acid (leucovorin, which enhances fluorouracil activity), and fluorouracil (5-FU, an antimetabolite that inhibits thymidylate synthase). This combination may be used in post-transplant patients with cancer or in clinical scenarios where both immunosuppression and cytotoxic chemotherapy are required. The mechanism of action involves both immune suppression (tacrolimus) and cytotoxic effects on rapidly dividing cells (FOLFOX4)[1][3][6].

Other names

tacrolimus and FOLFOX4tacrolimus plus FOLFOX4